Key Takeaway: Instil Bio, a clinical-stage biopharmaceutical company, announced its participation in the 2025 Jefferies Global Healthcare Conference. CEO Bronson Crouch will present on June 5, 2025, at 4:20 PM ET. The company is known for its lead asset, AXN-2510, a bispecific antibody targeting multiple solid tumors. A live webcast of the presentation will be available.
Price reaction · baseline $30.35 (2025-05-29 close) · hit pre-market · 1 other TIL headline(s) in the window, move may be shared
day 0 close
-11.2%
day 1
-2.3%
day 3 · peak
+13.3%
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Instil Bio is actively participating in a major healthcare conference.
The presentation will feature insights from the CEO, Bronson Crouch.
Instil is focused on developing innovative therapies for solid tumors.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~45 mo
Minimal dilution risk
Lead asset
AXN-2510
Phase 1 · Solid Tumor, Adult
Full Press Release Details
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 4:20PM ET on Thursday, June 5, 2025. A live webcast will be available using this weblink:https://wsw.com/webcast/jeff319/til/1708376.
About Instil BioInstil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visitwww.instilbio.com.
Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Frequently Asked Questions
When will Instil Bio present at the Jefferies Conference?
Instil Bio will present on June 5, 2025, at 4:20 PM ET.
Who is presenting for Instil Bio?
CEO Bronson Crouch will present at the conference.
What is Instil Bio's lead asset?
Instil Bio's lead asset is AXN-2510, a bispecific antibody.
Where can I watch the presentation?
A live webcast of the presentation will be available online.